Q-omics provides the consensus-scored PSMF1 profile across patient tissues and cancer cell-line models. PSMF1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PSMF1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PSMF1 RNA expression shows 18,483 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where PSMF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMF1 survival associations across molecular data types. PSMF1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMF1 RNA expression–survival associations across cancer types. High PSMF1 expression shows unfavorable associations in HNSC, LAML, COAD, LGG, LIHC and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for PSMF1 RNA expression.
This table summarizes PSMF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMF1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, COAD, STAD and LIHC. The HNSC box plot shows higher PSMF1 RNA expression in tumor versus normal tissue (log2 FC = +0.786, t-test p < 0.001).
This table shows molecular features associated with PSMF1 in patient tissues and cancer cell lines. In patient samples, PSMF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
